Rezolute, Inc. (NASDAQ:RZLT – Free Report) – Stock analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for shares of Rezolute in a research note issued on Wednesday, May 13th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $0.17 for the year, down from their previous forecast of $0.25. The consensus estimate for Rezolute’s current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Rezolute’s FY2030 earnings at $0.27 EPS.
Several other equities research analysts also recently commented on RZLT. Weiss Ratings reissued a “sell (d-)” rating on shares of Rezolute in a report on Tuesday, April 21st. Wedbush upgraded shares of Rezolute from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $2.00 to $5.00 in a report on Wednesday, March 25th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.00.
Rezolute Stock Performance
NASDAQ:RZLT opened at $3.33 on Thursday. The stock’s 50-day simple moving average is $3.13 and its 200 day simple moving average is $4.58. The company has a market cap of $318.68 million, a P/E ratio of -4.06 and a beta of 0.66. Rezolute has a 52-week low of $1.07 and a 52-week high of $11.46.
Rezolute (NASDAQ:RZLT – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01.
Hedge Funds Weigh In On Rezolute
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. New York State Common Retirement Fund grew its holdings in Rezolute by 5.6% during the third quarter. New York State Common Retirement Fund now owns 24,600 shares of the company’s stock worth $231,000 after purchasing an additional 1,300 shares during the period. JPMorgan Chase & Co. grew its holdings in Rezolute by 5.0% during the third quarter. JPMorgan Chase & Co. now owns 33,201 shares of the company’s stock worth $312,000 after purchasing an additional 1,567 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Rezolute by 5.5% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,659 shares of the company’s stock worth $363,000 after purchasing an additional 2,014 shares during the period. Huntleigh Advisors Inc. grew its holdings in Rezolute by 16.7% during the third quarter. Huntleigh Advisors Inc. now owns 17,500 shares of the company’s stock worth $164,000 after purchasing an additional 2,500 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Rezolute by 8.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 45,088 shares of the company’s stock worth $107,000 after purchasing an additional 3,630 shares during the period. Institutional investors own 82.97% of the company’s stock.
About Rezolute
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.
See Also
- Five stocks we like better than Rezolute
- Airplane Maintenance Companies That Keep Flights Moving Are Ready to Soar
- Oklo Stock Could Be Ready for Another Massive Run
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.
